Guggenheim analyst Yatin Suneja reiterated a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report) on June 16 and set a price target of $50.00. The company’s shares opened today at $6.18.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Suneja is a 4-star analyst with an average return of 6.3% and a 45.05% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Neurocrine, Regeneron, and Axsome Therapeutics.
Currently, the analyst consensus on Abivax SA Sponsored ADR is a Strong Buy with an average price target of $35.00, implying a 466.34% upside from current levels. In a report released on June 12, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target.
ABVX market cap is currently $386.4M and has a P/E ratio of -2.00.
Read More on ABVX:
- Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends
- Abivax SA Shareholders Approve 2024 Financials and Board Appointments
- Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst
- Abivax SA Reports Increased Losses Amid R&D Expansion
- Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue